Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 11NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Osteosarcoma 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Lung Neoplasms 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 31Carboplatin 29Cisplatin 28Paclitaxel 26Gemcitabine 14Docetaxel 14Etoposide 13Bevacizumab 9Ramucirumab 7Pemetrexed 6Magnetic Resonance Spectroscopy 5Erlotinib Hydrochloride 5Cetuximab 5pembrolizumab 4cediranib 4Vinorelbine 4Specimen Handling 4Radiosurgery 4Gene Expression Profiling 4Filgrastim 4Amplified Fragment Length Polymorphism Analysis 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Surgical Procedures, Operative 3Radiotherapy, Conformal 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lung Neoplasms × Sorafenib × Clear all
NCT00064350 2023-06-29

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
342 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡